Ungulate-derived polyclonal immunoglobulin specific for pd-li and uses thereof
AssigneeSab, LLC
InventorsChristoph L. BAUSCH, Hua Wu, Kristi A. EGLAND, Eddie J. SULLIVAN
Life of this patent
Estimating the term…
Abstract
Provided are human polyclonal immunoglobulin products specific for Programmed Death-Ligand 1 (PD-L1) for use in treating or preventing cancer. Further provided are methods for making such compositions in a transgenic ungulate, e.g. using a transchromosomic bovine (TcB) system.
Claims78
An ungulate-derived polyclonal human immunoglobulin composition, comprising a population of human immunoglobulins, wherein the population of human immunoglobulins specifically binds Programmed Death-Ligand 1 (PD-L1).
A method of making polyclonal human immunoglobulin specific for Programmed Death-Ligand 1 (PD-L1), comprising administering an antigenic fragment of PD-L1, or a polynucleotide encoding the antigenic fragment, to a transgenic ungulate,
- wherein the transgenic ungulate comprises a genome comprising a human immunoglobulin locus or an artificial chromosome comprising a human immunoglobulin locus, and wherein the transgenic ungulate produces a population of human immunoglobulins that specifically binds PD-L1.
A rabbit immunoglobulin composition, comprising a population of rabbit immunoglobulins, wherein the population rabbit immunoglobulins specifically binds Programmed Death-Ligand 1 (PD-L1).
A method of making polyclonal rabbit immunoglobulin specific for Programmed Death-Ligand 1 (PD-L1), comprising administering an antigenic fragment of PD-L1, or a polynucleotide encoding the antigenic fragment, to a rabbit,
- wherein the rabbit produces a population of rabbit immunoglobulins that specifically binds PD-L1.
Dependencies are inferred from the claim text.